Glutathione
What the Research Actually Shows
Human: 12 studies, 10 groups · Animal: 4 · In Vitro: 3
Your body already makes the most powerful antioxidant in biology. The question is whether injecting more of it actually helps—and the answer is more complicated than the wellness industry wants you to believe.
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
2Clinical Trials
3Pilot / Limited Human Data
4Preclinical Only
~It’s Complicated
Reasonable Bet
Eyes Open
Thin Ice
Glutathione is a small molecule made of three amino acids. Every cell in your body makes it. It is your main defense against the damage that oxygen causes to your cells, and it helps your liver break down toxins. Your levels drop as you age. That much is solid science. But swallowing glutathione pills barely works—your gut breaks it down before it reaches your blood. Liposomal versions absorb better, but the clinical proof is thin. IV glutathione bypasses the gut, but it clears your blood in minutes and has caused liver damage, severe allergic reactions, and worse in some patients. Most of the injection market is driven by skin lightening, not longevity. The molecule is essential. The injection is a gamble.
Glutathione is the most abundant non-protein thiol in mammalian cells—a tripeptide (γ-glutamylcysteinylglycine) present at millimolar concentrations in virtually every tissue. It is the body's primary antioxidant defense, the critical cofactor for Phase II detoxification in the liver, and a requirement for lymphocyte proliferation and natural killer cell activity. Without glutathione, cells cannot manage oxidative stress, cannot detoxify xenobiotics, and cannot mount effective immune responses. This is not marketing. This is undergraduate biochemistry.
The complication begins when you try to raise glutathione levels from the outside. Standard oral glutathione has dismal bioavailability—approximately 3–5%—because γ-glutamyl transpeptidase in the gut degrades it to its constituent amino acids before absorption. One well-designed RCT (Allen & Bradley, 2011) found no increase in blood glutathione after 500 mg twice daily for four weeks. Liposomal formulations substantially improve absorption (another RCT showed 30–35% blood increases at 6 months), but clinical outcome data remains thin. The precursor strategy—providing N-acetylcysteine to supply cysteine, the rate-limiting substrate for intracellular glutathione synthesis—may be the most pharmacologically rational approach, and it costs a fraction of what injectable glutathione costs.
IV glutathione bypasses the absorption problem entirely but introduces others. Plasma glutathione has a short half-life, clearing in minutes. To enter cells, exogenous glutathione must be degraded to its amino acid components and resynthesized intracellularly—the same pathway as oral absorption, just starting from a higher plasma level. More concerning, IV glutathione carries real safety signals: hepatotoxicity, anaphylaxis, Stevens-Johnson syndrome, and at least one documented case of full systemic inflammatory response syndrome after high-dose infusion. The FDA issued a safety alert in 2019 specifically about compounding sterile injectables from dietary-grade glutathione powder.
This article covers the full evidence landscape: the unassailable biology, the bioavailability problem, the clinical trial data (such as it is), and the honest gap between what glutathione does inside your cells and what happens when you inject it from outside.
Table of Contents
Quick Facts: Glutathione at a Glance
Type
Endogenous tripeptide antioxidant
Also Known As
GSH, L-glutathione, reduced glutathione, γ-glutamylcysteinylglycine
Generic Name
Glutathione (no INN)
Brand Name
Setria (oral, Kyowa Hakko), various liposomal brands. No branded injectable.
Molecular Weight
307.3 g/mol
Route
Oral (poor bioavailability unless liposomal). IV infusion (bypasses gut, short plasma half-life, safety concerns). Subcutaneous (community protocol, no published data). Topical (skin lightening, limited absorption). Intranasal (Parkinson's, one negative RCT).
WADA Status
Not prohibited. Not on the 2026 WADA Prohibited List.
Key Researchers
Alton Meister (Cornell—foundational GSH biochemistry, γ-glutamyl cycle). Rajagopal Sekhar (Baylor—GlyNAC aging research). Dean Jones (Emory—redox biology). Robert Hauser (USF—Parkinson's IV glutathione RCT).
Peptide Sequence
γ-Glu-Cys-Gly. Three amino acids, but bonded through glutamate's γ-carboxyl group (not the standard α-carboxyl). This non-standard bond makes glutathione resistant to normal peptidases—an elegant evolutionary solution to prevent degradation by the same enzymes it protects against.
Endogenous Origin
Synthesized de novo by every cell. Two-step ATP-dependent pathway: γ-glutamylcysteine synthetase (rate-limiting, cysteine-dependent) → glutathione synthetase. Intracellular concentration: 1–10 mM. The most abundant intracellular thiol in biology.
Primary Molecular Function
Antioxidant (glutathione peroxidase cycle: GSH → GSSG, reducing H2O2 and lipid hydroperoxides). Phase II detoxification (glutathione S-transferase conjugation). Immune regulation (T-cell proliferation, NK cell activity). Protein thiol maintenance.
Clinical Programs
Small RCTs for Parkinson's disease (IV, negative), skin lightening (oral, positive for melanin), type 2 diabetes (oral, small positive), immune function (liposomal, open-label). No large Phase III trial for any indication.
Redox Forms
Reduced (GSH) is the active form. Oxidized (GSSG) is the spent form. GSH/GSSG ratio is the primary readout of cellular redox status. Healthy cells maintain >90% GSH.
Related Compounds
N-Acetylcysteine / NAC (precursor—provides cysteine for GSH synthesis, well-studied, cheap). GlyNAC (glycine + NAC combo, emerging). S-Acetyl Glutathione (modified for improved oral absorption, limited clinical data). Liposomal glutathione (improved oral bioavailability).
FDA Status
GRAS for oral dietary supplement (FDA GRAS Notice No. 244). NOT FDA-approved as a drug. FDA safety alert (2019) against compounding sterile injectables from dietary-grade glutathione. Under review for 503A/503B bulk drug substance lists.
Community Interest
Very high, driven primarily by the skin-lightening market (Southeast Asia, globally). Secondary interest from longevity and "detox" communities. IV glutathione is a staple at wellness clinics worldwide.
The NAC Question
N-acetylcysteine (NAC) at 600–1800 mg/day raises intracellular glutathione by providing the rate-limiting cysteine substrate. NAC is well-studied, cheap, and widely available. The clinical case for injecting glutathione directly—rather than taking NAC orally—has not been established in any published controlled trial.
Evidence Tier
3 Pilot / Limited Human Data
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
What Is Glutathione?
Pronunciation: gloo-tuh-THY-own
Every cell in your body runs on oxygen, and every cell in your body is damaged by oxygen. This is the paradox of aerobic life. The same molecule that fuels mitochondrial energy production generates reactive oxygen species (ROS) as a byproduct—superoxide, hydrogen peroxide, hydroxyl radicals. These molecules damage DNA, denature proteins, and oxidize lipid membranes. Left unchecked, they destroy cells. You need a defense system that runs continuously, in every cell, at concentrations high enough to neutralize ROS the instant they form.
That system is glutathione. It is a tripeptide—three amino acids: glutamate, cysteine, and glycine, molecular weight 307 daltons—and it is the most abundant non-protein thiol in biology. Intracellular concentrations range from 1 to 10 millimolar, making it more concentrated than most metabolites. The thiol group on its cysteine residue is the business end: it donates an electron to reactive oxygen species, neutralizing them, and in the process glutathione itself becomes oxidized (GSH → GSSG). The enzyme glutathione reductase then regenerates GSH from GSSG using NADPH as an electron donor, completing the cycle.
But glutathione does more than quench free radicals. It is the critical cofactor for Phase II detoxification—glutathione S-transferases conjugate glutathione to electrophilic toxins, drugs, and environmental chemicals, tagging them for excretion. It is required for lymphocyte proliferation. It maintains the reduced state of protein thiols, preventing misfolded protein aggregation. And it participates in the γ-glutamyl cycle, a transport system that moves amino acids across cell membranes.
PLAIN ENGLISH
Glutathione is your body's cleanup crew for the damage that comes from breathing oxygen. Every cell makes it. Every cell needs it. When levels drop—from aging, illness, or toxic exposure—damage accumulates faster than your cells can fix it. The entire debate about glutathione supplements is whether adding more from the outside actually helps when your cells are already making it on the inside.
Origins and Discovery
Glutathione was first identified in 1888 by J. de Rey-Pailhade, who called it "philothion" (sulfur-loving). Frederick Gowland Hopkins at Cambridge characterized its chemical structure in 1921 and gave it the name glutathione. But the full biochemistry—synthesis, cycling, transport, enzymatic partnerships—was largely worked out between the 1960s and 1980s, primarily by Alton Meister at Cornell University.
Meister's work established the γ-glutamyl cycle, characterized both biosynthetic enzymes (γ-glutamylcysteine synthetase and glutathione synthetase), and developed buthionine sulfoximine (BSO), the specific inhibitor of glutathione synthesis that enabled researchers to study what happens when cells run out. The answer: rapid oxidative damage, mitochondrial failure, and cell death. BSO experiments in animal models proved beyond question that glutathione is essential for survival.
The clinical interest in glutathione supplementation began in the 1990s with two observations. First, glutathione levels decline with aging—a finding replicated across species and tissues. Second, glutathione is severely depleted in the substantia nigra of Parkinson's disease patients, and this depletion appears to precede neuronal loss. These observations launched a line of research into whether replenishing glutathione could slow neurodegeneration—a hypothesis that, 30 years later, remains unproven despite several clinical attempts.
The third wave of commercial interest, beginning in the 2000s, was driven by the discovery that glutathione inhibits melanin synthesis. Oral and IV glutathione became widely used for skin lightening, particularly in Southeast Asia. This cosmetic application—not longevity, not Parkinson's—now drives the majority of the global glutathione injection market.
PLAIN ENGLISH
Glutathione was discovered over a century ago. The basic science was mostly solved by the 1980s. The unsolved question—whether putting more glutathione into your body from the outside actually makes a difference—has been asked for 30 years without a definitive answer.
Mechanism of Action
The Glutathione Peroxidase Cycle
The core antioxidant function: glutathione peroxidase (GPx) uses GSH to reduce hydrogen peroxide (H2O2) to water and lipid hydroperoxides to alcohols. Two molecules of GSH are oxidized to one molecule of GSSG in each reaction. Glutathione reductase then regenerates GSH from GSSG using NADPH from the pentose phosphate pathway. This cycle runs continuously in every cell, with the GSH/GSSG ratio serving as the primary readout of cellular redox balance. A healthy cell maintains >90% of its glutathione in the reduced (GSH) form.
Phase II Detoxification
Glutathione S-transferases (GSTs) catalyze the conjugation of glutathione to electrophilic compounds—drugs (acetaminophen), environmental toxins (heavy metals, pesticides), and endogenous metabolites (lipid peroxides). The glutathione conjugate is water-soluble and can be excreted. This is the liver's primary detoxification mechanism, and glutathione depletion is directly linked to susceptibility to drug-induced liver injury (the mechanism behind acetaminophen overdose hepatotoxicity—NAC works as an antidote because it replenishes glutathione).
Immune Regulation
T-cell proliferation requires adequate intracellular glutathione. NK cell cytotoxicity correlates with GSH levels. HIV infection depletes glutathione systemically, contributing to immune dysfunction. Richie et al. (2015) demonstrated that oral glutathione supplementation (1000 mg/day × 6 months) doubled natural killer cell cytotoxicity in healthy adults—one of the more compelling clinical findings.
The Melanin Pathway
Glutathione inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis. It also shifts melanogenesis from eumelanin (dark pigment) to pheomelanin (light pigment). This mechanism underlies the skin-lightening effect and is the basis for the cosmetic glutathione market.
PLAIN ENGLISH
Glutathione does three big jobs: (1) neutralize the damage oxygen causes, (2) help your liver break down toxins and drugs, and (3) support your immune system. It also lightens skin—which is why most people who inject it are not doing it for longevity.
Key Research Areas and Studies
Oral Glutathione—Body Stores and Immune Function
Richie et al. (2015, PMID 24791752): 54 healthy adults randomized to oral glutathione (250 or 1000 mg/day) or placebo × 6 months. High-dose group: GSH increased 30–35% in erythrocytes, plasma, and lymphocytes; 260% in buccal cells. NK cell cytotoxicity doubled at 3 months. This is the strongest positive oral glutathione trial.
Allen & Bradley (2011, PMID 21875351): 40 healthy adults, oral glutathione 500 mg BID × 4 weeks. NO increase in blood GSH. No reduction in oxidative stress markers. Negative study. Important because it demonstrates the bioavailability problem with standard (non-liposomal) oral glutathione.
Sinha et al. (2018, PMID 28853742): 12 healthy adults, liposomal oral glutathione (500/1000 mg/day × 1–2 weeks). Blood GSH increased 40%, NK cell cytotoxicity improved 2×, T-cell proliferation increased. Open-label, no control group. Suggests liposomal formulation addresses the bioavailability problem, but uncontrolled design limits conclusions.
IV Glutathione—Parkinson's Disease
Sechi et al. (1996, PMID 8938817): 9 patients with early PD, IV glutathione 600 mg BID × 30 days. All patients improved (42% decline in disability). Landmark study, but NO control group, NO randomization. The study that launched IV glutathione for PD.
Hauser et al. (2009, PMID 19230029): 21 PD patients randomized to IV glutathione (1400 mg 3×/week × 4 weeks) or placebo. Well tolerated. NO significant difference in UPDRS scores between groups. The only controlled IV glutathione trial in PD—and it was negative.
Mischley et al. (2017): 45 PD patients randomized to intranasal glutathione or placebo. Both groups improved. No significant between-group difference. Negative for intranasal route.
Skin Lightening
Wattanathom et al. (2010, PMID 20524875): 60 Thai women, oral glutathione 500 mg/day × 4 weeks vs. placebo. Significant reduction in melanin index at 6 body sites. First controlled skin-lightening RCT.
Arjinpathana & Asawanonda (2012, PMID 22781378): 60 subjects, oral glutathione 500 mg/day × 4 weeks. Reduced UV spots and melanin.
Sonthalia & Sarkar Systematic Review (2024, PMID 39444151): 5 RCTs. Oral glutathione shows significant but variable melanin reduction. Long-term safety not established.
Precursor Strategy (GlyNAC)
Sekhar et al. (2021, PMID 34017922): 24 older adults randomized to GlyNAC (glycine + N-acetylcysteine, GSH precursors) or placebo × 16 weeks. GlyNAC improved mitochondrial function, insulin resistance, inflammation, and physical function. NOT exogenous glutathione—this is the precursor strategy, providing building blocks for cells to make their own GSH. Among the most impressive "glutathione-adjacent" clinical data.
PLAIN ENGLISH
The best clinical results for raising glutathione actually come from giving your body the raw materials to make its own—not from injecting the finished product. GlyNAC (glycine plus NAC) improved multiple aging markers in a controlled trial. The only controlled IV glutathione trial in Parkinson's was negative.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “Glutathione is the body's master antioxidant” | Established biochemistry. GSH is the most abundant intracellular thiol and the primary substrate for glutathione peroxidase. Textbook. | Supported |
| “Glutathione levels decline with aging” | Consistent finding across species and tissues. Well-replicated. | Supported |
| “IV glutathione treats Parkinson's disease” | One uncontrolled pilot (n=9) was positive. The only RCT (n=21) was negative. Intranasal RCT was also negative. No credible evidence of efficacy. | Unsupported |
| “Oral glutathione boosts immune function” | One RCT (Richie, n=54) showed doubled NK cell cytotoxicity at high dose. Open-label liposomal study showed similar. Promising but not replicated. | Mixed Evidence |
| “IV glutathione is a powerful "detox"” | No controlled trial has tested "detox" as an endpoint. Glutathione's role in Phase II detoxification is real endogenously, but adding exogenous IV GSH has not been shown to enhance detoxification above baseline. | Unsupported |
| “Glutathione lightens skin” | Multiple RCTs confirm melanin reduction with oral glutathione. Mechanism (tyrosinase inhibition) is understood. Effect is real but variable. | Supported |
| “Subcutaneous glutathione is effective” | No published data. Zero trials, zero PK studies. Community protocol with no evidence basis. | Unsupported |
| “IV glutathione is safe” | FDA safety alert (2019). Case reports of hepatotoxicity, anaphylaxis, Stevens-Johnson syndrome, SIRS. The only RCT (n=21) reported no serious events, but it was small and short. Safety profile is NOT well-established for IV route. | Mixed Evidence |
| “Liposomal glutathione is as good as IV” | No head-to-head trial. Liposomal GSH raises blood levels (Richie 2015, Sinha 2018) and is better tolerated. Whether it produces equivalent tissue levels or clinical outcomes is unknown. | Preclinical Only |
| “You need glutathione supplements because your body can't make enough” | Your body synthesizes glutathione continuously. The rate-limiting factor is cysteine availability. NAC (N-acetylcysteine) at 600–1800 mg/day provides cysteine and effectively raises intracellular GSH at a fraction of the cost. The necessity of exogenous GSH over the precursor strategy has not been demonstrated. | Unsupported |
The Human Evidence Landscape
The human evidence for glutathione supplementation is fragmented—dozens of small trials scattered across different routes, formulations, indications, and populations, with no unifying large trial. For oral glutathione, the picture is mixed: the Richie trial (n=54, 6 months, positive for GSH levels and NK cell activity) conflicts with the Allen trial (n=40, 4 weeks, negative for GSH levels). The difference likely reflects formulation quality, dose, and duration. Liposomal formulations appear to overcome the bioavailability barrier, but the liposomal data comes from small, mostly uncontrolled studies.
For IV glutathione, the evidence is worse. The only controlled trial in any indication (Hauser in Parkinson's, n=21) was negative. The positive Sechi pilot (n=9, 1996) had no control group and has never been replicated in a controlled design in 30 years. Intranasal glutathione for PD was also negative. The entire clinical case for IV glutathione rests on an uncontrolled pilot from 1996 and mechanistic plausibility.
The skin-lightening data is the strongest: five RCTs consistently show melanin reduction with oral glutathione at 500 mg/day for 4–12 weeks. This is a cosmetic endpoint with a clear mechanism (tyrosinase inhibition). It tells you nothing about longevity, neuroprotection, or "detox."
The GlyNAC approach (Sekhar, Baylor) may represent the most promising direction—using glutathione precursors rather than exogenous glutathione. The controlled trial showed broad improvements in aging biomarkers. This approach is pharmacologically rational (it lets cells synthesize GSH where they need it), well-tolerated, and inexpensive.
PLAIN ENGLISH
If this compound were being evaluated solely on the IV injection evidence—which is how most vendor customers encounter it—it would be a Tier 4 compound. The small positive human studies for oral glutathione and the strong biology are what keep it at Tier 3.
Safety, Risks, and Limitations
Oral Glutathione Safety (Adequate Data)
- Well tolerated at 250–1000 mg/day in RCTs up to 6 months.
- Mild GI symptoms (nausea, bloating) in some subjects.
- No hepatotoxicity at oral doses in published trials.
- FDA GRAS status for dietary supplement use.
- Long-term safety (>6 months) not established.
IV Glutathione Safety (Concerning Signals—Critical Disclaimer Warranted)
- Hepatotoxicity: A 2025 review reported nearly one-third of patients in one case series developed liver function abnormalities. Individual case reports of acute liver injury.
- Anaphylaxis: Documented case reports of severe allergic reactions.
- Stevens-Johnson syndrome: Documented—a potentially life-threatening skin reaction.
- Systemic inflammatory response syndrome (SIRS): 2025 case report after high-dose unregulated infusion—fever >41°C, inflammatory marker surge, coagulopathy.
- FDA safety alert (2019): Adverse events linked to IV glutathione compounded from dietary-supplement-grade powder (not appropriate for sterile injectables).
- Short plasma half-life: GSH clears in minutes. Benefits (if any) are transient, requiring repeated infusions.
- Quality control: Compounding pharmacies and gray-market vendors use variable source materials. The FDA alert specifically flagged the use of dietary-grade (non-sterile, non-pharmaceutical-grade) glutathione for injection.
Subcutaneous Glutathione Safety (No Data)
- No published safety data. Zero controlled trials.
- Community protocols adapted from IV dosing without pharmacokinetic justification.
The NAC Safety Comparison
- NAC (600–1800 mg/day oral) is well-studied for decades, used clinically for acetaminophen overdose (IV), mucolytic therapy, and as a supplement. Safety profile is well-established. Cost is a fraction of glutathione injection.
Legal and Regulatory Status
Glutathione has FDA GRAS status for use as an oral dietary supplement (GRAS Notice No. 244). It is NOT FDA-approved as a drug for any indication. The FDA issued a specific safety alert in June 2019 regarding the compounding of sterile glutathione injectables from dietary-supplement-grade powder, noting adverse event reports in patients receiving these products.
Glutathione's status on the FDA's 503A/503B bulk drug substance lists is under review by the Pharmacy Compounding Advisory Committee (PCAC reviewed in June 2022). Some compounding pharmacies continue to compound injectable glutathione, but its regulatory path is not settled. The Philippines FDA and other international regulators have issued warnings about unregistered glutathione injection products, particularly those marketed for skin lightening.
Research Protocols and Laboratory Practices
Glutathione is water-soluble and available as a white crystalline powder (reduced form). It oxidizes on exposure to air, so lyophilized/powder forms should be stored sealed, desiccated, at 2–8°C (35–46°F). Reconstituted solutions are unstable—oxidation to GSSG begins immediately. IV infusions should be prepared immediately before administration. No published protocol exists for subcutaneous glutathione.
For research purposes, glutathione levels are measured via: - GSH/GSSG ratio in blood (erythrocytes, plasma, PBMCs)—the standard clinical endpoint - Buccal cell GSH (used in Richie 2015 as a tissue proxy) - Enzymatic recycling assay (Tietze method) or HPLC
Dosing in Published Research
| Study/Source | Population | Dose | Route | Frequency | Duration | Key Findings |
|---|---|---|---|---|---|---|
| Richie 2015 | Healthy adults | 250 or 1000 mg | Oral | Daily | 6 months | GSH ↑ 30–35%, NK cytotoxicity doubled |
| Allen 2011 | Healthy adults | 500 mg | Oral | BID | 4 weeks | No increase in GSH (negative) |
| Sinha 2018 | Healthy adults | 500–1000 mg liposomal | Oral | Daily | 1–2 weeks | GSH ↑ 40%, NK ↑ 2× (open-label) |
| Sechi 1996 | Early PD | 600 mg | IV | BID | 30 days | 42% disability improvement (uncontrolled) |
| Hauser 2009 | PD | 1400 mg | IV | 3×/week | 4 weeks | No improvement vs. placebo (negative RCT) |
| Mischley 2017 | PD | 100–200 mg | Intranasal | 2×/day | 3 months | No improvement vs. placebo (negative RCT) |
| Wattanathom 2010 | Healthy women | 500 mg | Oral | Daily | 4 weeks | Melanin index reduced (skin lightening) |
| Sadat 2022 | Type 2 diabetes | 250 mg | Oral | Daily | 6 months | HbA1c improved, oxidative markers reduced |
| Sekhar 2021 | Older adults | GlyNAC (precursors) | Oral | Daily | 16 weeks | Improved mitochondrial function, insulin resistance |
Dosing in Independent Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
The following table summarizes community-reported dosing practices for Glutathione. These are not clinical recommendations. No controlled trial data supports these protocols.
| Protocol Parameter | Typical Community Range | Notes |
|---|---|---|
| Oral (standard) | 250–1000 mg/day | Poor bioavailability (~3–5%). Cheap. Wide availability. |
| Oral (liposomal) | 250–1000 mg/day | Better absorption (50–90%). More expensive. Growing popularity. |
| Oral (S-acetyl glutathione) | 100–300 mg/day | Modified for stability. Limited clinical data. |
| NAC (precursor) | 600–1800 mg/day | Most cost-effective. Well-studied. Provides rate-limiting cysteine. |
| GlyNAC (precursor combo) | Glycine 1.33 mmol/kg + NAC 0.81 mmol/kg/day | Per Sekhar 2021 protocol. Most promising precursor approach. |
| IV glutathione | 600–2000 mg per infusion | 1–3× per week at wellness clinics. $100–$500 per session. |
| IV (skin lightening) | 600–2400 mg per infusion | Weekly–biweekly × 6–12 sessions. Cosmetic market. |
| Subcutaneous | 200–600 mg, 2–3× per week | Self-administered. Adapted from IV. No published protocol. |
[WHY NEARLY EMPTY—Gold callout]: Published research on injectable glutathione is limited to a handful of IV studies in Parkinson's disease (the only RCT was negative) and no published studies for subcutaneous administration. Community IV protocols for "detox" and longevity have zero controlled trial support. Skin-lightening protocols have RCT support for the oral route but not for IV. The NAC/GlyNAC precursor strategy has better clinical evidence than any glutathione injection protocol.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Glutathione combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Glutathione with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Frequently Asked Questions
Is glutathione a peptide?
Yes—technically. Glutathione is a tripeptide: three amino acids (glutamate, cysteine, glycine) joined by peptide bonds. But one of those bonds is non-standard: the glutamate connects through its γ-carboxyl group instead of the usual α-carboxyl. This makes glutathione resistant to normal peptidases, which is why your body can use it as an intracellular workhorse without it being immediately broken down.
Should I take glutathione or NAC?
This is not medical advice. What the evidence shows: NAC at 600–1800 mg/day effectively raises intracellular glutathione by providing the rate-limiting amino acid (cysteine) for your cells to synthesize their own GSH. NAC is well-studied, well-tolerated, cheap, and widely available. No controlled trial has demonstrated that exogenous glutathione (oral or injected) produces superior clinical outcomes compared to NAC. The GlyNAC combination (glycine + NAC) has the strongest clinical trial data of any glutathione-raising strategy.
Does IV glutathione work for Parkinson's?
One uncontrolled pilot (n=9, 1996) showed dramatic improvement, but it had no control group. The only randomized controlled trial (n=21, 2009) found no significant difference between IV glutathione and placebo. An intranasal RCT was also negative. The current evidence does not support IV glutathione as a treatment for Parkinson's disease.
Why is oral glutathione bioavailability so low?
γ-Glutamyl transpeptidase (GGT) on the surface of intestinal cells breaks down glutathione into its three amino acids before it can be absorbed intact. Your gut literally dismantles the molecule as a normal part of the amino acid recycling system (the γ-glutamyl cycle). Liposomal encapsulation protects glutathione from GGT, which is why liposomal formulations achieve much better absorption.
Is IV glutathione safe?
The safety profile is not well-established. The FDA issued a 2019 safety alert about IV glutathione compounded from dietary-grade powder. Case reports document hepatotoxicity, anaphylaxis, Stevens-Johnson syndrome, and systemic inflammatory response. The only controlled IV trial (n=21) reported no serious events, but it was small and short. Oral glutathione at standard doses has a much better-documented safety profile.
Does glutathione really lighten skin?
Yes—multiple RCTs show reduced melanin index with oral glutathione at 500 mg/day. The mechanism is understood: glutathione inhibits tyrosinase and shifts melanin production from dark (eumelanin) to light (pheomelanin) pigment. The effect is modest, variable, and requires continuous supplementation. Long-term safety of skin-lightening doses is not established.
How much does glutathione decline with age?
This varies by tissue and individual, but age-related decline in GSH levels is a consistent finding across species. Contributing factors include decreased synthesis (lower γ-glutamylcysteine synthetase activity), increased oxidative stress (more GSH consumed), and decreased cysteine availability.
What about glutathione for "detox"?
Glutathione is genuinely essential for Phase II detoxification—this is established biochemistry. But your liver's detoxification capacity depends on intracellular glutathione, not circulating glutathione. IV glutathione raises plasma levels transiently. Whether this translates to increased hepatic detoxification above what your liver already provides has never been tested in a controlled trial. The "detox" marketing of IV glutathione is mechanistically plausible but clinically unproven.
Can glutathione cause liver damage?
Paradoxically, yes—despite glutathione's hepatoprotective role endogenously. Case reports and one review suggest that IV glutathione can cause liver function abnormalities, possibly through rapid redox shifts or contaminants in non-pharmaceutical-grade preparations. Oral glutathione has not been associated with hepatotoxicity in published trials.
What is GlyNAC and why does it matter?
GlyNAC is a combination of glycine and N-acetylcysteine—the two amino acid precursors that cells need to synthesize glutathione (glutamate, the third component, is abundant and rarely rate-limiting). Rajagopal Sekhar's lab at Baylor showed that GlyNAC supplementation in older adults improved mitochondrial function, insulin resistance, inflammation, and physical function in a controlled trial. It is the most pharmacologically rational approach to glutathione repletion because it lets cells make GSH where and when they need it.
Why is glutathione sold as a "peptide" by injection vendors?
Glutathione is technically a tripeptide—three amino acids joined by peptide bonds. But it is not a signaling peptide like BPC-157 or humanin. It does not bind a receptor and trigger a downstream cascade. It is a metabolic workhorse—a redox molecule that your cells use and recycle continuously. Vendors sell it alongside peptides because the delivery method (subcutaneous or IV injection) overlaps with the peptide market. The distinction matters: the pharmacological logic for injecting a signaling peptide (to activate a specific receptor) is different from the logic for injecting a metabolic cofactor (which your cells already make at millimolar concentrations).
Is there any evidence that injectable glutathione works better than oral for longevity?
No. No controlled trial has compared injectable glutathione to oral glutathione (or to NAC or GlyNAC) for any longevity-related endpoint. IV glutathione bypasses the gut absorption problem, but plasma glutathione clears in minutes—the molecule must be broken down and resynthesized inside cells regardless of how it enters the blood. The only controlled IV trial (Hauser 2009, Parkinson's) was negative. The most impressive clinical data in the glutathione space comes from oral GlyNAC (Sekhar 2021), not from injections.
Summary of Key Findings
Glutathione is not a compound where the science is in question. Its biology is settled. Every cell makes it, every cell needs it, and depletion causes real damage. The question—and the reason this article exists—is whether the products sold as "glutathione supplements" effectively restore what aging and disease deplete.
What the evidence supports: - Glutathione is the body's primary antioxidant and detoxification cofactor (textbook). - Levels decline with aging (well-replicated). - High-dose oral glutathione (1000 mg/day, 6 months) raises blood GSH levels and may improve NK cell function (one RCT). - Liposomal oral glutathione improves bioavailability over standard formulations (limited data). - Oral glutathione reduces melanin (skin lightening, multiple RCTs). - GlyNAC (glycine + NAC, precursor strategy) improved multiple aging markers in a controlled trial.
What the evidence does not support: - That IV glutathione treats Parkinson's disease (only RCT was negative). - That IV glutathione provides meaningful "detox" beyond endogenous capacity (no controlled trial). - That subcutaneous glutathione is effective (zero published data). - That injecting glutathione is superior to taking NAC orally (never tested head-to-head). - That IV glutathione is safe (concerning case reports, FDA safety alert).
The honest assessment: If your goal is to raise intracellular glutathione, the evidence supports oral NAC or GlyNAC—not because the data is overwhelming, but because it is the most pharmacologically rational approach, the best-studied, the cheapest, and the safest. If you are injecting IV or subcutaneous glutathione, you are using a product with thinner evidence, higher cost, and real safety concerns. The biology of glutathione is beyond question. The products built on that biology are not.
Verdict Recapitulation
Glutathione carries an Evidence Tier of 3—Pilot/Limited Human Data, reflecting several small RCTs with narrow endpoints and one negative controlled IV trial. The overall verdict is Eyes Open: the endogenous biology is textbook, oral precursors (NAC, GlyNAC) offer a rational and safer path, but injectable glutathione products carry real safety signals and thin efficacy data.
For readers considering Glutathione, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Glutathione
Further Reading and Resources
If you want to go deeper on Glutathione, the evidence landscape for longevity & anti-aging peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Longevity & Anti-Aging Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Glutathione — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Richie JP Jr, et al. (2015). Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. PMID 24791752
- Allen J, Bradley RD. (2011). Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. Journal of Alternative and Complementary Medicine. PMID 21875351
- Sinha R, et al. (2018). Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. European Journal of Clinical Nutrition. PMID 28853742
- Hauser RA, et al. (2009). Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Movement Disorders. PMID 19230029
- Sechi GP, et al. (1996). Reduced intravenous glutathione in the treatment of early Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry. PMID 8938817
- Sekhar RV, et al. (2021). GlyNAC supplementation improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, aging hallmarks, metabolic defects, and body composition in older humans. Journal of Nutrition. PMID 34017922
- Wattanathom S, et al. (2010). Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. Journal of Dermatological Treatment. PMID 20524875
- Sonthalia S, Sarkar R. (2024). Glutathione as a skin-lightening agent and in melasma: a systematic review. International Journal of Dermatology. PMID 39444151
- Meister A. (1991). Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacology & Therapeutics
- Mischley LK, et al. (2017). Central nervous system uptake of intranasal glutathione in Parkinson's disease. npj Parkinson's Disease
- Arjinpathana N, Asawanonda P. (2012). Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. Journal of Dermatological Treatment. PMID 22781378
- Sadat S, et al. (2022). Randomized clinical trial of how long-term glutathione supplementation offers protection from oxidative damage and improves HbA1c in elderly type 2 diabetic patients. Antioxidants
DISCLAIMER
Glutathione is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 05, 2026. Next scheduled review: October 02, 2026.